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Abstract: Neuropathic pain is a common symptom and is associated with an impaired quality of
life. It is caused by the lesion or disease of the somatosensory system. Neuropathic pain syndromes
can be subdivided into two categories: central and peripheral neuropathic pain. The present review
highlights the peripheral neuropathic models, including spared nerve injury, spinal nerve ligation,
partial sciatic nerve injury, diabetes-induced neuropathy, chemotherapy-induced neuropathy, chronic
constriction injury, and related conditions. The drugs which are currently used to attenuate peripheral
neuropathy, such as antidepressants, anticonvulsants, baclofen, and clonidine, are associated with
adverse side effects. These negative side effects necessitate the investigation of alternative therapeutics
for treating neuropathic pain conditions. Flavonoids have been reported to alleviate neuropathic
pain in murine models. The present review elucidates that several flavonoids attenuate different
peripheral neuropathic pain conditions at behavioral, electrophysiological, biochemical and molecular
biological levels in different murine models. Therefore, the flavonoids hold future promise and can
be effectively used in treating or mitigating peripheral neuropathic conditions. Thus, future studies
should focus on the structure-activity relationships among different categories of flavonoids and
develop therapeutic products that enhance their antineuropathic effects.
Keywords: chemotherapy-induced peripheral neuropathy; chronic constriction injury; diabetic
neuropathy; diabetic painful neuropathy; flavonoids; oxidative stress; partial sciatic nerve injury;
peripheral neuropathy; spared nerve injury; spinal nerve ligation
1. Introduction
Pain is defined as “an unpleasant sensory and emotional experience associated with actual or
potential tissue damage, as described in terms of such damage” by the International Association
for the Study of Pain [1]. Pain has been classified as acute vs. chronic based on duration only, not
location or cause; bone or joint, cutaneous, deep or superficial, muscle or viscera based on location;
and inflammatory, neuropathic or cancer based on cause or type [2]. Pain is relayed to the spinal cord
by nociceptors, which are specialized primary afferent neurons capable of detecting noxious chemical,
mechanical, and thermal stimuli [3]. According to the National Center for Complementary and
Integrative Health, 11 million US adults suffer with “high impact chronic pain” [4]. Neuropathic pain
is one of the most intense types of chronic pain conditions, resulting from the lesion in a somatosensory
nervous system, which comprises of peripheral fibers (Aβ, Aδ and C fibres) and central neurons [5].
It affects 6.9–10% of the general population as reported in a systematic review conducted by van
Hecke et al. [6]. The prevalence of neuropathic pain has increased 60% in severe clinical neuropathic
conditions [7]. Most of the published data on neuropathic pain conditions mainly are based on studies
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in participants with low back pain [8–10], diabetes [11], nerve entrapment syndrome [8], as well as
patients who attended neurology pain centers [12]. In the UK, the data indicated the prevalence
of neuropathic pain to be 8% [13]. In United States, the prevalence rates of neuropathic pain were
determined as 9.8% and 12.4% based on either clinical examination or self-reporting, respectively.
However, the true estimate of neuropathic pain is difficult to obtain due to differences in defining
neuropathic pain as well as differences in epidemiological methods used for assessment [14].
Central and peripheral are the two main types of neuropathic pain. Central encompasses central
lesion, spinal cord injury, and diseases like stroke, multiple sclerosis [5], whereas peripheral includes
peripheral nerve damage or injury [15]. Numerous studies have reported the effectiveness of tricyclic
antidepressants, dextromethorphan, gabapentin, lamotrigine, phenytoin, pregabalin, opioids, and
tramadol for treating painful sensory neuropathy [16,17]. These therapies reduce pain by 30–50% but
are accompanied by side effects, such as sedation. For gabapentinoids, the number needed to treat
neuropathic pain, in most of the meta-analyses fall between 7 and 10 [18]. Furthermore, the American
Academy of Neurology recommends not to use opioids and sodium valproate in neuropathic pain [19].
Despite advances in pain research by employing combinatorial chemistries and high throughput
screening techniques over past 50 years, natural products like plant secondary metabolites remain
important molecules of interest in the treatment of different pain conditions [20]. The need for alternative
agents, such as natural products with effective and safe analgesic properties, satisfactory tolerability, and
proven efficacy in treating pain conditions, has been growing throughout the world [21–24]. The present
review will focus on the flavonoids, mainly anthocyanins, chalcones, flavanones, flavones, flavonols,
flavan-3-ol, and isoflavones and their effects on different peripheral neuropathic pain conditions.
2. Flavonoids Classification, Structure, and Dietary Sources
Table 1 lists the chemical structures of different sub-groups of flavonoids. The basic structure of
flavonoid includes 15 carbon atoms in their backbone, arranged in the form of C6-C3-C6 backbone
with two aromatic rings (A and B) linked to each other by three carbon atoms, which may or may not
give rise to the third carbon atom, which may or may not form the third ring. Flavonoids are further
classified into different sub-groups, such as anthocyanins, chalcones, flavanones, flavones, flavonols,
flavan-3-ol, and isoflavones based on the hydroxylation pattern and chromane ring/ring C.
Table 2 summarizes the different sub-groups of flavonoids along with their examples and dietary
sources. Anthocyanins are responsible for contributing colors in flowers, fruits, vegetables, and
certain grains like black rice. The color of the anthocyanin is dependent on pH in which the red is
formed under acidic condition, whereas blue is formed under basic condition as well as acylation and
methylation of hydroxyl groups on A and B rings [25]. The most commonly reported anthocyanins,
such as cyanidin, delphinidin and pelargonidin, and their methylated derivatives constitute 90% of
total anthocyanin. The hydroxylation and methylation patterns on the B ring and glycosylation with
different sugar units constitute more than 500 known anthocyanidins [26,27]. Chalcones are referred
to as open-chain flavonoids due to the absence of the basic C ring from the flavonoid backbone. The
major chalcones are arbutin, chalconaringenin, phloretin, and phloridzin. Chalcones are present in
various fruits, such as apples, berries, strawberries, pears, tomatoes, certain wheat products, and hops
or beers [28,29]. In case of isoflavones, the B ring attached to the C3 position of C ring. Biochanin A,
daidzein, formononetin, genistein, and glycitein, and puerarin are major isoflavones. Isoflavones are
predominantly found in Leguminous plants, mainly in soybeans.
Another sub-group of flavonoids are flavanonols or dihydroflavonols, which include flavanones
and their 3-hydroxy derivatives. The C ring in flavanones is saturated, which marks the difference
between flavanone and flavone. The commonly reported flavanones are eriodictyol, hesperetin, and
naringenin. Flavanones are generally present in citrus fruits. Taxifolin is an example of a well-known
flavanonol found in citrus fruit [30,31]. Flavones, including their 3-hydrozy derivatives (flavonols),
glycosides, methoxides, and other acylated products constitute the largest sub-group among all
polyphenols. Flavones contain double bonds between positions 2 and 3 and a ketone in position 4 of
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the C ring. Flavones of the fruits and vegetables contain hydroxyl group in the 5 position of the A ring,
sometimes hydroxyl group is present in 7 position of the A ring or 3′ and 4′ of the B ring, or other
positions. Flavones are found as glycosides in flowers, fruits, leaves, and are also present in celery,
chamomile, parsley, and red peppers. Apigenin, baicalein, isoorientin, luteolin, and tangeretin belong
to flavone. Polymethoxylated flavones, such as tageretin, nobiletin and sinensetin are found in peels of
the citrus fruit [32]. Flavonols contain hydroxyl group in 3 position of the C ring, which might also be
glycosylated. Flavonols also possess different hydroxylation, glycosylation and methylation patterns.
Flavonols are found in teas, red wine, along with a variety of fruits and vegetables, such as apples,
berries, grapes, kale, lettuce, onions, and tomatoes. The most commonly studied flavonols are fisetin,
kaempferol, morin, myricetin, and quercetin. Icariin is a prenylated flavonol glycoside, which is
isolated from a traditional Chinese medicinal herb Epimedium and is used to treat bone fractures and
osteoporosis [33]. On the other hand, flavanols are also known as flavan-3-ol because a hydroxyl group
is always bound at the 3 position of ring C. Unlike flavonoids, there is no double bond between C2 and
C3, and no C4 carbonyl in ring C of flavonols. The presence of hydroxylation at C3 enables flavonols to
have two chiral centers on the C2 and C3 molecules, hence four possible diastereoisomers. Catechin is
the isomer with trans configuration along with two stereoisomers (+)-catechin, (−)-catechin. Epicatechin
is the cis configuration with two stereoisomers (+)-epicatechin and (−)-epicatechin. Flavanols are
found in skins of fruits like apple, bananas, blueberries, grapes, peaches and pears. Catechins, such as
epicatechin, epigallocatechin, epicatechin gallate, and epigallocatechin gallate (EGCG) are found in
commercially available dietary supplements, beverages, as well as whole and processed foods [34,35].
Oligomeric proanthocyanidins can be A-type or B-type structure based on the interflavanic
linkages. The monomers are linked through C2–O–C7 or C2–O–C5 bonding in A-type structure,
whereas the bonding involves C4–C6 or C4–C8 in B-type structure. The common procyanidin dimers
and trimers include procyanidin B1, procyanidin B2, procyanidin A2, and procyanidin C1, which is a
trimer. Unique dimers like theaflavin are formed when tea flavanols are fermented [36,37].
Table 1. Chemical structures of different sub-groups of flavonoids.
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Table 2. Different sub-groups, examples, and dietary sources of flavonoids.
Flavonoid
Subgroup Example Dietary Sources References
Anthocyanins
Cyanidin Edible red (red clover, red hibiscus, red pineapple sage,
pink blossom); blue (blue chicory, blue rosemary,
cornflower); purple (purple mint, purple passionflower,
purple sage); berries, blackcurrants, black carrot, purple
potato, red cabbage
Khoo et al. [25]
Delphinidin
Pelargonidin
Peonidin
Petunidin
Malvidin
Chalcones
Arbutin
Hops, hop containing beers and herbal teas Stevens et al. [38];
Zhao et al. [29]
Chalconaringenin
Phloretin
Phloridzin
Xanthohumol
Flavanones
Eriodictyol
Citrus fruits like lemon, lime mandarin, orange; grapefruit,
herbal tea (Honeybush tea), potato
Tomás-Barberán &
Clifford [39]
Hesperetin
Hesperidin
Naringenin
Flavones
Apigenin Engelhardt et al., 1993 [40];
Carnat et al., 2004 [41];
Caristi et al., 2006 [42];
Wojdylo et al., 2007 [43];
Wijaya & Mares, 2012 [44];
Pereira-Caro et al., 2013 [45];
Magalhães et al. [46]
Baicalein
Diosmin
Isoorientin
Luteolin
Nobiletin
Tangeretin
Dry herbs and teas (Roman Chamomile flowers, tansy leaf,
fenugreek seed, rosemary, sage, black tea, green tea,
oolong tea); juices and wines (bergamot juice, mandarin
orange juice, citron juice, orange juice); fruits, vegetables,
olive oil and honey (kiwi, spinach, parsley, celery, lettuce,
artichoke, broccoli, watermelon, pumpkin, peas); cereals
and legumes (chickpea, fava pea, field pea, wheat grain,
black, brown, red and white rice)
Flavonols
Fisetin
Fruits (apples, berries, grapes), vegetables (curly kale, leek,
lettuce, onions, tomatoes), tea, red wine
Egert & Rimbach [47]
Isorhamnetin
Kaempferol
Morin
Myricetin
Quercetin
Flavan-3-ol
Catechin
Dietary supplements, beverages, whole and processed
foods
Prior et al. [34]; Si et al. [35](−)-Epicatechin
Epigallocatechin
gallate
Isoflavones
Biochanin A
Kidney beans, lentils, mung bean sprouts, mung beans,
red clover, soy products, soybeans, soy products
Ho et al. [48]; Zaheer and
Akhtar [49]
Daidzein
Formononetin
Genistein
Glycitein
Puerarin
3. Biosynthesis of Flavonoids
Flavonoids are synthesized through the phenylpropanoid pathway by the transformation of
phenylalanine into 4-coumaroyl-CoA, which enter the flavonoid biosynthesis pathway. All flavonoids
are derived from the chalcone scaffold, which is biosynthesized by the enzyme chalcone synthase (CHS).
The enzyme CHS catalyzes the condensation and subsequent intramolecular cyclization of three acetate
units onto the p-coumaroyl-CoA, which is the end product of the general phenylpropanoid pathway.
Following the enzymatic reaction catalyzed by CHS, oxoglutarate-dependent Fe2+/3+ dioxygenases,
hydroxylases, isomerases, and reductases modify the basic flavonoid backbone and lead to the synthesis
of a variety of flavonoid subclasses, such as anthocyanins, chalcones, flavanones, flavones, flavonols,
and isoflavones. Chalcone isomerase stereospecifically directs the additional cyclization of chalcones
to form flavones.
The acyltransferases, glycosyltransferases, and methyltransferases add acyl, sugar, and/or methyl
moieties, respectively, and thus alter the solubility, reactivity, and interactions of flavonoids with
different cellular targets [50,51].
4. Neuropathic Pain
Neuropathic pain is defined as “pain caused by a lesion or disease of the somatosensory nervous
system” by the International Association for the Study of Pain [52]. Somatosensory nerves arise from
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fascia, joints, muscles, skin, and include various receptors, like thermoreceptors, mechanoreceptors,
chemoreceptors, pruriceptors, and nociceptors that send signals to the spinal cord and eventually to
the brain for further processing [5]. Neuropathic pain is difficult to treat effectively and is associated
with significant impairment of health conditions and economic burden [53,54]. One of the largest
studies on neuropathic pain conducted in US showed the prevalence rate of neuropathic pain being
9.8% among adults in Minnesota [55].
Neuropathic syndrome can be divided into two categories: peripheral and central neuropathic
pain conditions. Central neuropathic pain is due to a lesion or disease of the spinal cord and/or
brain. Cerebrovascular disease like central post-stroke pain (CPSP) affects the central somatosensory
pathway as well as the neurodegenerative diseases mainly Parkinson disease cause central neuropathic
pain [56]. Furthermore, spinal cord lesion or diseases like multiple sclerosis, transverse myelitis and
neuromyelitis optica, spinal cord injury, and syringomyelia lead to neuropathic pain [57].
The consequences of peripheral lesion or disease lead to the development of peripheral neuropathic
conditions, respectively. The pathology of peripheral disorders, which cause neuropathic pain,
mainly involve unmyelinated C fibers and myelinated Aβ and Aδ fibers [58]. Some of the common
and typically irreversible peripheral neuropathic conditions include alcoholic neuropathy, cancer
pain, Charcot-Marie-Tooth disease, chemotherapy-induced peripheral neuropathy (CIPN), chronic
inflammatory demyelinating polyneuropathy, complex regional pain syndrome, diabetic painful
neuropathy (DPN), human immunodeficiency virus painful sensory neuropathy, phantom limb pain,
post-herpetic neuralgia, erythromelalgia, and many more.
5. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
The use of different chemotherapy agents and other cancer treatments will lead to the damage
of the nerves away from the brain and spinal cord. CIPN is one of the most common neuropathies
caused by antineoplastic agents [59]. The prevalence of CIPN is age-related, varying from 19% to
more than 85% [60]. The highest incidence of CIPN has been reported in the case of platinum-based
(70–100%), taxanes (11–87%), thalidomide and its analogues (20–60%), and ixabepilone (60–65%) [61].
The common symptoms for CIPN include sensitivity to cold and heat, tingling or pins-and-needles
sensation, pain, burning, or numbness, difficulty with fine motor skills, and muscle weakness [62]. In
general, CIPN symptoms arise after weeks or months after completion of the chemotherapy, mainly
dependent on the cumulative dose of the drug [63]. Paclitaxel and oxaliplatin induce severe neuropathy
during or immediately after infusion [64].
Effects of Flavonoids on CIPN
Table 3 summarized the effects of flavonoids on CIPN. Platinum compounds play an important
antitumor drug that is widely used in the treatment of various solid tumors. Cisplatin was the
first synthesized drug in 1864 after carboplatin. Oxaliplatin is a third-generation platinum drug
with significant cytotoxicity and diminished antitumoral resistance [65,66]. Azevedo et al. [67]
reported that quercetin and rutin inhibited oxaliplatin-induced cold and mechanical nociceptive
thresholds. The histopathological analysis of the skin harvested from the paws of the mice subjected to
oxaliplatin-induced peripheral neuropathy showed that quercetin and rutin prevented the formation
of little lacunar spaces between collagen fibers. Quercetin or rutin also prevented oxaliplatin-induced
lipid peroxidation reflected by malondialdehyde (MDA) levels in the spinal cord samples. Finally,
immunohistochemical analysis of the dorsal horn of the spinal cord showed that both quercetin and
rutin reduced Fos expression, whereas only quercetin inhibited nitrotyrosine, and inducible nitric
oxide synthase (iNOS) immunoexpression. Schwingel et al. [68] reported that quercetin nanoemulsion,
and rutin reduced oxaliplatin-induced mechanical allodynia. Furthermore, the study showed that
quercetin, quercetin nanoemulsion, and rutin decreased the nociceptive biomarker c-Fos in the
spinal cord, indicating that phytochemicals modulated the oxaliplatin-induced neuropathy at the
central level [58]. The antinociceptive activity of 6-methoxyflavone was investigated in a rat model
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of CIPN [69]. Thereby, 6-methoxyflavone significantly attenuated cisplatin-induced mechanical
allodynia by increasing paw withdrawal threshold and thermal hypoalgesia by alleviating paw
thermal threshold. Further, 6-methoxyflavone induced antinociceptive activity was without associated
side effects, such as motor impairment exemplified by rotarod endurance latency [69]. In another
study, naringin prevented cisplatin-induced behavioral impairment and anxiolytic-like behavior
in the elevated T-maze test. Treatment of naringin significantly and dose-dependently prevented
various biochemical and molecular alterations in the aged rats treated with cisplatin. Naringin
prevented the increase in acetylcholinesterase activity and decrease Na+, K+-ATPase, Ca2+-ATPase,
and Mg2+-ATPase activities induced by cisplatin in hippocampus. Administration of naringin with
cisplatin significantly reduced oxidative biomarkers, such as lipid peroxidation, protein carbonylation,
and hydrogen peroxide formation, in the hippocampus of aged rats. Naringin together with cisplatin
prevented the increase in reactive oxygen species (ROS), nitric oxide (NO) level, messenger ribonucleic
acid (mRNA) expression of iNOS, alteration of nonenzymatic (ascorbic acid, GSH) and antioxidant
enzymes, such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx)
activities in the hippocampus in aged rats [70]. The above study summarized the effects of naringenin
in cisplatin-induced oxidative-stress-mediated inflammation in cognitive dysfunction and cognitive
deficits in chemotherapy-induced peripheral neuropathy [70].
Flavonoids have also been reported in ameliorating neuropathic manifestation induced by
paclitaxel [71–73]. Gao et al. [71] reported that quercetin significantly increased thermal hyperalgesia
and mechanical allodynia in both paclitaxel treated rats and mice. In vitro treatment of quercetin
on RBL-2H3 cells dose-dependently and significantly decreased the release of histamine, whereas
in vivo quercetin treatment significantly reduced histamine release in the plasma of rats. Quercetin also
dose-dependently decreased the protein expressions of protein kinase Cε (PKCε) and transient receptor
potential V1 ion channels (TRPV1) in spinal cord and dorsal root ganglion (DRG) neurons of rats and
spinal cords of mice. Furthermore, forty days of both low and high dose of quercetin treatments inhibited
the translocation of PKCε from the cytoplasm to the membrane in the spinal cord and DRG of paclitaxel
treated rats. Gui et al. [74] found that icariin treatment significantly alleviated paclitaxel-induced
mechanical allodynia in the long term by suppressing the expressions of pro-inflammatory markers,
such as tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), and interleukin 6 (IL-6), astrocytes
activation, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) phosphorylation
(p65) in the spinal cord. Icariin also reversed paclitaxel-induced downregulation of spinal sirtuin
1 (SIRT1) expression and H4 acetylation. Activation of SIRT1 and H4-K16 acetylation in the spinal
cord has been reported to alleviate neuropathic pain [75]. Therefore, the study concluded that icariin
suppressed paclitaxel-induced neuroinflammation and mechanical allodynia in a SIRT-1-dependent
manner. Nadipelly et al. [72] reported the effects of four trimethoxy flavones in paclitaxel-induced
peripheral neuropathy in mice. The flavones dose-dependently attenuated paclitaxel-induced tactile
allodynia, cold allodynia and thermal hyperalgesia in mice. Flavones dose-dependently inhibited
the expression of TNFα and IL-1β with IC50 values ranged from 60.13 µM, to 90.82 µM and 33–72
µM, respectively. Moreover, the flavones dose-dependently decreased 2,2-diphenyl-1-picrylhydrazyl
(DPPH) free radicals with IC50 values ranging from 58.82–61.21 µM. The NO generation was also
inhibited by the flavones with IC50 ranging from 32.39–74.59 µM [72]. Li et al. [76] reported that
methoxy-substituted flavones have a better bioavailability than hydroxy flavones. Therefore, the
antinociceptive activities of trimethoxy flavones against paclitaxel-induced peripheral neuropathy
could be attributed to the structure-activity relationship of flavonoids, which might enhance their
antinociceptive properties. In a similar study, flavonol and its dimethoxy derivatives does-dependently
attenuated paclitaxel-induced tactile allodynia, cold allodynia and thermal hyperalgesia in mice along
with decrease in pro-inflammatory cytokines TNFα and IL-1β and free radicals, such as DPPH and
NO in a dose-dependent manner [73].
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Table 3. Effects of flavonoids on chemotherapy-induced peripheral neuropathy (CIPN).
Flavonoids Animals Dose mg/kg (Route ofAdministration) Effects/Mechanisms of Action Reference
Behavioral Evaluation Biochemical/Molecular Parameters
Icariin
Male Sprague
Dawley rats
25, 50, and 100 mg/kg ↓ Paclitaxel-induced mechanical
allodynia in long term
↓ Paclitaxel-induced increase of TNF-α, IL-1β, and
IL-6, astrocytes, NF-κB (p65) phosphorylation in
spinal cord
Gui et al. [74]
Intrathecal Reversed paclitaxel-induced downregulation ofSIRT1 expression and H4 acetylation
7,2′,3′-trimethoxy flavone,
7,2′,4′-trimethoxy flavone,
7,3′,4′-trimethoxy flavone and
7,5,4′-trimethoxy flavone
Swiss albino mice
Either sex
25, 50, 100 and 200 mg/kg ↓ Paclitaxel-induced tactile allodynia,
cold allodynia and thermal
hyperalgesia
X Proinflammatory cytokines (TNFα, IL-1β) and
free radicals (DPPH, NO)
Nadipelly et al. [72]Subcutaneous
20, 30, 60, 120, 240 µM—in vitro
Flavonol, 3′,4′-dimethoxy flavonol,
6,3′-dimethoxy flavonol,
7,2′-dimethoxy flavonol and
7,3′-dimethoxy flavonol
Male Swiss albino
mice
25,50, 100, and 200 mg/kg
↓ Tactile allodynia, cold allodynia and
thermal hyperalgesia X TNFα, IL-1β, DPPH, NO
Sayeli et al. [73]Subcutaneous
20, 30, 60, 120, 240 µM—in vitro
6-methoxyflavone
Male
Sprague-Dawley
rats
25, 50 and 75 mg/kg ↓ Cisplatin-induced mechanicalallodynia and heat hypoalgesia - Shahid et al. [69]
Intraperitoneal Elicited no detectable deficit in motorcontrol
Quercetin
Male
Sprague-Dawley
rats and mice
20 and 60 mg/kg ↑ Heat hyperalgesia and mechanical
allodynia in paclitaxel-treated rats and
mice
↓ Expressions of PKCε and TRPV1 in spinal cords
and DRGs of paclitaxel-treated rats and mice Gao et al. [71]
Intraperitoneal
X Translocation of PKCε from cytoplasm to
membrane in spinal cord and DRG in
paclitaxel-treated rats and mice
3, 10, 30 µM/L and 20 and 60
µM/L—in vitro
↓ Histamine release in RBL-2H3 cells in vitro as
well as in plasma of quercetin-treated rats
Naringin Wistar rats. Sex
not specified
25, 50, and 100 mg/kg
Cisplatin with naringin prevented
behavioral impairment observed in
only cisplatin treated group
X Cisplatin-induced increase in
acetylcholinesterase Chtourou et al. [70]
↓ Na+, K+-ATPase, Ca2+-ATPase, and
Mg2+-ATPase activities
Oral gavage X Cisplatin-induced anxiogenic effectin elevated T-maze test
Altered oxidative biomarkers, antioxidant
enzymes, nonenzymatic antioxidant, increase in
ROS, iNOS mRNA expression, and NO levels in
hippocampus
Quercetin, quercetin nanoemulsion,
and rutin
Male BALB/c mice
Quercetin, quercetin
nanoemulsion, and rutin (20
mg/kg)
↓ Oxaliplatin-induced mechanical
allodynia
↓ Nociceptive biomarker c-Fos in dorsal horn of
spinal cord
Schwingel et al. [68]
Oral gavage
Quercetin and rutin Male Swiss mice
Rutin and quercetin (25, 50, and
100 mg/kg)
X Oxaliplatin-induced peripheral
neuropathy
X Lipid peroxidation, tyrosine nitrosylation, and
peroxynitrite-associated neuronal damage Azevedo et al. [67]
Intraperitoneal
↑ = Increased, ↓ = Attenuated/Decreased/Reduced/Suppressed, X = Inhibited/Prevented.
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In summary, flavonoids have inhibited CIPN by attenuating pain behaviors along with inhibiting
pro-inflammatory biomarkers as well as pronociceptive signaling pathways and downstream effectors.
Flavonoids can be used in attenuating CIPN.
6. Diabetic Painful Neuropathy
Diabetic neuropathy is one of the leading causes of neuropathy. According to the International
Diabetes Federation, it affects 382 million people worldwide [77]. According to an international
meeting on the diagnosis and management of diabetes defined diabetic peripheral neuropathy as “the
presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the
exclusion of other causes” [77]. Patients with diabetic neuropathy are characterized with burning,
excruciating stabbing kind of pain, numbness, tingling sensation, and might also be associated with
paraesthesia and hyperesthesia coupled with the aching of feet or hands [78,79].
Metabolic and vascular are the two major factors for the pathogenesis of diabetic neuropathy.
Hyperglycemia leads to the accumulation of fructose and sorbitol due to increased activity of enzyme
aldose reductase that confers the rate limiting step in polyol pathway. Hyperglycemia also results in
the disturbance of several metabolic pathways, such as advanced glycation end products (AGE) [80,81],
hexosamine [82], polyol [83,84], protein kinase C (PKC) [85,86], and poly-ADP ribose polymerase
(PARP) [87,88] pathways in the nervous system. The pathways contribute in neuronal and axonal
injury in diabetic neuropathy as well as increased level of oxidative stress in nervous system of
diabetic neuropathy. These above-mentioned pathways also induce the production of ROS through
mitochondria. The metabolic pathways and oxidative stress lead to the activation of NF-κB and
specialty protein-1, resulting in neuroinflammation and vascular impairment.
Effects of Flavonoids on Diabetic Painful Neuropathy
Table 4 reviews the effects of different flavonoids on diabetic painful neuropathy. Catechin [89],
luteolin [90], pelargonidin [91], rutin [92], and genistein [93] have been reported to reduce the MDA
levels in diabetic animal. MDA has been considered as a primary biomarker for free radical-mediated
lipid damage and oxidative stress. The elevated level of MDA has been reported in the serum and
other tissues of diabetic patients, impacting the peripheral nerve [94,95].
The flavonoids catechin [89], naringenin [96], morin [97], kaempferol [98], luteolin [90], rutin [92],
genistein [93], hesperidin, and fisetin [99] have been shown to decrease the level of ROS by increase
the level of different antioxidative enzymes, such as SOD, CAT, reduced glutathione peroxidase
(GSH), GPx and glutathione reductase (GR) in different tissues (brain, liver, sciatic nerve) of diabetic
animals. Furthermore, luteolin, morin and rutin have shown to increase the expression of nuclear
factor-E2-related factor-2 (Nrf2) Nrf2 and its downstream effectors heme oxygenase-1 (HO-1) in nerve
tissues of diabetic animals. Nrf-2/HO-1 plays a protective role against oxidative stress-induced damage
and neuroinflammation in diabetic animals [100–102]. Kaempferol reduced AGEs and EGCG reduced
8-hydroxy-2-deoxyguanosine (8-OHdG), which is one of the predominant forms of free radical-induced
oxidative lesions in mitochondrial and nuclear DNA [103]. Naringenin and genistein increased nerve
growth factor (NGF) in sciatic nerves of diabetic animals. NGF plays important role in life maintenance
and survival of the neurons. Decline in NGF induces peripheral nerve lesions like axonal atrophy,
demyelination, and reduced number of nerve fibers in diabetic patients [104]. Kishore et al. [98]
reported that kaempferol reduced the NO level in diabetic animals. Besides modulating different
oxidative stress biomarkers, flavonoids morin, puerin and rutin reduced the expression of NF-κB, and
especially morin prevented the phosphorylation of inhibitor kappa kinase (IKK) and thus prevented
the translocation and expression of NF-κB. Several flavonoids decreased the levels of proinflammatory
cytokines, like tumor necrosis factor-alpha (TNFα), interleukin-1beta (IL-1β), interleukin-6 (IL-6), and
transforming growth factor β (TGF-β).
Matrix metalloprotease 9 (MMP-9) plays an important role in neuropathic pain and is associated
with neuroinflammation and oxidative stress [105–107]. MMP-9 is activated by ROS produced at the
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site of injury. ROS inhibitor N-acetyl-cysteine suppress has been shown to suppress the expression
of MMP-9 and attenuate neuropathic pain [108,109]. Catechin [89] has been shown to reduce the
circulatory MMP-9 in diabetic rats.
Diabetic neuropathy in rodents have also been characterized by assessing behavioral markers,
which include thermal, mechanical, chemical hyperalgesia, tactile allodynia in sensory large fibers,
and sensory motors deficit in large sensory fibers [110]. The neuropathic assessment showed that
flavonoids significantly downregulated chemical, mechanical, thermal hyperalgesia and allodynia in
diabetic rodents. Several flavonoids, such as naringenin [96], naringin [111], luteolin [90], baicalin [112],
pelargonidin [91], rutin [92], hesperidin [113], and fisetin [99], attenuated diabetes-induced thermal
hyperalgesia, whereas morin [97], naringenin [96], naringin [111], kaempferol [98], luteolin [90],
epigallocatechin gallate [114], and rutin [92] reduced mechanical hyperalgesia. In addition to
hyperalgesia, morin [97], baicalein [112], puerarin [115], hesperidin [113], and fisetin [99] reduced
mechanical allodynia, whereas, genistein [93] and naringin [111] reduced mechano-tactile allodynia,
and luteolin [90] and rutin [92] reduced cold allodynia. Studies have shown that short term diabetes
induced thermal, chemical and mechanical hyperalgesia [116,117], whereas long term diabetes induces
thermal and mechanical hypoalgesia [118]. Baicalein ameliorated thermal hypoalgesia [119].
Electrophysiological measurements are employed in order to determine the sensory and motor
nerve function, which include the assessment of motor and sensory nerve conduction in the tail and
sciatic nerve. Sensory nerve conduction velocity (SNCV) is used to determine sensory nerves status in
all the parameters measured in nerve conduction studies. SNCV accurately reflects the myelin integrity
and axon caliber [120]. SNCV is slowed by the demyelination of the sensory nerve fibers. SNCV and
motor nerve conduction velocity (MNCV) are both slow in diabetic animals. The etiology of nerve
dysfunction is attributed to both vascular and non-vascular mechanisms [121]. Flavonoids, such as
morin [97], rutin [92], hesperidin [113], and baicalein [119] increased both MNCV and SNCV, whereas
kaempferol [98] only increased MNCV. Grape seed proanthocyanidins and its metabolites catechin and
epicatechin [122] and luteolin [90] improved nerve conduction velocity in the sciatic nerve in diabetic
neuropathy. Morin [97] and luteolin [90] improved nerve function by increasing nerve blood flow.
Besides attenuating oxidative stress biomarkers, pro-inflammatory cytokines, behavioral markers,
and improving nerve function, flavonoid catechin increased body weight compared to diabetic animals,
reduced heart hypertrophy, and reduced diabetic-induced increase in plasma glucose level [89]. Blood
glucose level was also reduced by kaempferol [98], rutin [92], naringenin [96], and luteolin [90].
However, EGCG [114] and genistein [93] showed no effects on body weight and blood glucose level
compared to diabetic animals. The diabetes induced body weight loss and increased plasma glucose
level were ameliorated by naringenin [96]. GSPs improved diabetic parameters emphasizing mainly
on LDL, which was improved when compared with diabetic control ones [122].
In conclusion, these different flavonoids can be used as the potential treatments for diabetic
neuropathy. Flavonoids attenuate diabetic neuropathy by modulating different diabetic parameters,
oxidative stress biomarkers, pro-inflammatory cytokines, behavioral markers, and nerve function in
diabetic neuropathy.
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Table 4. Effects of flavonoids on diabetic painful neuropathy (DPN).
Flavonoids Animals
Flavonoids (Dose
mg/kg and Route of
Administration)
Effects/Mechanisms of Action Reference
Behavioral Evaluation/Other Diabetic
Parameters
Electrophysiological/
Functional
Evaluation
Histopathological/Biochemical/Molecular
Parameters
Catechin Male Sprague Dawley
rats
25 mg/kg and 50
mg/kg
↑ Body weight compared to diabetic
animals -
Improved hemodynamic parameters (heart rate, mean
atrial pressure and left ventricular systolic pressure),
oxidative stress parameters (MDA, GSH, CAT, SOD)
Addepalli et al. [89]
Intraperitoneal ↓ Heart hypertrophy, plasma glucoselevels
Reversed diabetes-induced neuronal damage and
reduced circulatory MMP-9
Morin
Male
Sprague-Dawley rats
50 and 100 mg/kg
↓Mechanical hyperalgesia and
mechanical allodynia
Improved
measurement of
MNCV, SNCV, and
nerve blood flow
(NBF)
↑Mitochondrial-specific superoxide dismutase 2
(SOD2) expression in high glucose-treated N2A cells
Bachewal et al. [97]
Oral gavage
↓ Glucose-induced ROS generation by increasing
expression of Nrf2 and its downstream effectors NQO1
and HO-1 in N2A cells
10 and 20
µM—In vitro
↓ IKK (ser176/180) phosphorylation, levels of TNFα
and IL-6
X Translocation and expression of NF-κB in N2A cells
↓ Levels of TNFα and IL-6
Grape seed
proanthocyanidins
(GSPs) and its
metabolites C
(+)-catechin; EC,
(−)-epicatechin
Male
Sprague-Dawley rats
250 mg/kg
GSPs - Improved diabetic parameters,
especially low-density lipoprotein level
GSPs—↑ Nerve
conduction velocity
(NCV) in sciatic/tibial
nerves
GSPs—↑ Normal mitochondria, endoplasmic reticulum
in sciatic nerves and partially improved myelin sheath
morphology
Ding et al. [122]
Oral
GSPs—↓ Free Ca2+ concentrations and ER stress
markers (GRP78, CHOP, phospho-JNK, total JNK and
cleaved caspase-12)
(+)-catechin; EC,
(−)-epicatechin
GSPs treated cells showed similar cell viability, LDH
release extent, apoptosis/necrosis cell fractions to
treatment with serum treated from healthy rats
2.5, 5, 10 µM
C and EC—Partially ameliorated cell injury in cells
treated with serum from diabetic rats
C and EC—X Cell injury, Ca2+ overload and ER stress
Kaempferol Male Wistar rats 5 and 10 mg/kg
↓ Blood glucose level at the end of the
study (90 days) ↑MNCV compared to
diabetic control rats
↑ Levels of GSH, SOD, and thiobarbituric acid reactive
substances (TBARS) Kishore et al. [98]
↑ Diabetes-induced thermal and
mechanical hyperalgesia ↓ NO level, sciatic AGEs, TNF-α, TGF-β and IL-1β
Baicalin
Male
Sprague-Dawley rats
10, 20, and 40 µg/kg ↓ Diabetes-induced mechanical
allodynia and thermal hyperalgesia
- ↓ Both mRNA and protein expressions of TRPV1 in
DRG of diabetic rats
Li et al. [112]
Intraperitoneal
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Table 4. Cont.
Flavonoids Animals
Flavonoids (Dose
mg/kg and Route of
Administration)
Effects/Mechanisms of Action Reference
Behavioral Evaluation/Other Diabetic
Parameters
Electrophysiological/
Functional
Evaluation
Histopathological/Biochemical/Molecular
Parameters
6-Methoxyflavanone
Female
Sprague-Dawley rats
and BALB/c mice
10 and 30 mg/kg
No acute toxicity in animals ascertained
by a lack of cyanosis, ataxia, convulsions,
writhing or mortality -
Thermal antinociception was antagonized by opioid
receptor antagonist naloxone and GABA antagonist
pentylenetetrazole
Akbar et al. [123]
Intraperitoneal
↓ Thermal nociception in
streptozotocin-induced diabetic
neuropathy model at 30- and 60-min
post-treatment
Elicited anti-allodynic and
anti-vulvodynic effects
Rutin
Male
Sprague-Dawley rats
5, 25, and 50 mg/kg ↓ Plasma glucose level ↑MNCV and SNCV
in diabetic rats
↑ Na+, K+-ATPase activities in sciatic nerves
Tian et al. [92]
↓ Caspase-3 expression in DRG neurons
↓MDA and ROS levels
Partially increased antioxidant enzymes SOD, GPx,
glutathione-S-transferase (GST), and CAT in sciatic
nerves
↑ H2S, Nrf2 and HO-1 in DRG neurons
Intraperitoneal
↓ Diabetes-induced mechanical
hyperalgesia, thermal hyperalgesia, and
cold allodynia
↓ NF-κB, IкBα, p-IкBα, IL-6 and TNF-α in DRG
neurons of diabetic rats
Naringenin Male Wister albino
25 and 50 mg/kg/day
X Fasting blood glucose level and high
dose of naringenin increased insulin
level
-
↓ TNFα, IL-1β and IL-6, NO level
Al-Rejaie et al. [96]
↓ Elevated TBARS in sciatic nerves
↑ GSH, SOD, CAT, GPx and GR levels in sciatic nerves
Improved decreased sciatic expressions of insulin
growth factor and NGF levels in sciatic nerves
Intraperitoneal
Improved mechanical and thermal
hyperalgesia by increasing tail and paw
withdrawal latency time
In histological analyses, low dose—partial focal
peripheral axonal loss and regenerating thin
myelinated axons, indicative of mild degenerative and
regenerative neuropathy high dose—minimal axonal
degenerative changes without regenerative features,
indicative of minor degenerative neuropathy
Luteolin
Male
Sprague-Dawley rats
50 mg/kg, 100 mg/kg
and 200 mg/kg ↓ Plasma glucose levels
Improved nerve
function by increasing
nerve blood flow
(NBF) and nerve
conduction velocity
(NCV)
↓ ROS and MDA levels Li et al. [90]
Intraperitoneal ↓ Diabetes-induced cold allodynia andmechanical and thermal hyperalgesia
↑ Antioxidant enzymes SOD, GST, GPx and CAT along
with Nrf2 and HO-1 in nerve tissues in diabetic rats
Epigallocatechin-gallate
(EGCG) Male Wistar rats
2 g/L
Did not affect blood glucose
concentration, body weight or liquid
intake compared to diabetic animals
-
X Increase of (8-hydroxy-2-deoxyguanosine (8-OHdG)
immunoreaction and Fos expression in spinal cord Raposo et al. [114]
Oral gavage Ameliorated diabetes-induced tactileallodynia and mechanical hyperalgesia
X Higher percentage of 8-OHdG-IR cells that
co-localized with Fos
Molecules 2020, 25, 1171 15 of 36
Table 4. Cont.
Flavonoids Animals
Flavonoids (Dose
mg/kg and Route of
Administration)
Effects/Mechanisms of Action Reference
Behavioral Evaluation/Other Diabetic
Parameters
Electrophysiological/
Functional
Evaluation
Histopathological/Biochemical/Molecular
Parameters
Fisetin Male C57BL/6J mice
10 mg/kg ↑ Body weight and slightly decreased
food/water intake -
↓ Exacerbated oxidative stress by reducing lipid
peroxide, ROS production
Zhao et al. [99]↑ Increased CAT activity in spinal cord, DRG, and
sciatic nerve
Co-administration of ROS donor tert-butyl
hydroperoxide(t-BOOH) abrogated antinociceptive
activity
Co-administration of ROS scavenger
phenyl-N-tert-butylnitrone potentiated antinociceptive
activity
Oral gavage Ameliorated diabetes-induced thermalhyperalgesia and mechanical allodynia
Intrathecal administration of GABAA receptor
antagonist bicuculline attenuated antinociceptive
activity although or GABAB receptor antagonist
phaclofen did not alter antinociceptive activity
Puerarin
Male
Sprague-Dawley rats
4, 20, and 100 nM Did not affect mechanical withdrawal
threshold -
↓ NF-κB, IL-6, IL-1β, and TNF-α in spinal cord
Liu et al. [115]X Activation of microglia and astroglia in spinal cord
Intrathecal
↓ Diabetes-induced mechanical
allodynia
↓ Diabetes-induced elevation of TNF-α, IL-1β, and IL-6
and NF-κB DNA binding activities
X Overexpression of NF-κB p65 and p65 nucleus
translocation
Hesperidin
Sprague Dawley rats 25, 50 and 100 mg/kg X Body weight loss, increased plasma
glucose level, elevated intake of food
and water and urine output
↑MNCV and SNCV
compared to diabetic
rats
↓ Serum glucosuria, cholesterol, and triglyceride levels
Visnagri et al. [113]
Sex not specified Oral gavage
↓ Elevated glycated hemoglobin and aldose reductase
levels, hemodynamic parameters (SBP, DBP, and MABP,
neural lipid peroxidase, NO, and total calcium levels)
↑ Serum insulin, neural SOD, glutathione, and
Na+K+ATPase levels
↑ Plasma glucose level compared to
diabetic rats ↓mRNA expressions of TNF-α and IL-1β
↑ Diabetes-induced mechano-tactile
allodynia and thermal hyperalgesia
Restored diabetes-induced histological aberrations by
reducing infiltration of neutrophil and macrophages
Naringin Male Wistar rats
40 and 80 mg/kg
Ameliorated decreased body weights
and increased plasma glucose level
↑MNCV ↑ SOD level Kandhare et al. [111]
↓ Diabetes-induced increase in food
intake, water intake, and urine output
Intraperitoneal
↓ Decrease in diabetes-induced
mechano-tactile allodynia, mechanical
hyperalgesia, and thermal hyperalgesia
↓ TNFα, lipid peroxide, elevated neural nitrite,
Na-K-ATPase levels along with percentage of apoptosis
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Table 4. Cont.
Flavonoids Animals
Flavonoids (Dose
mg/kg and Route of
Administration)
Effects/Mechanisms of Action Reference
Behavioral Evaluation/Other Diabetic
Parameters
Electrophysiological/
Functional
Evaluation
Histopathological/Biochemical/Molecular
Parameters
Baicalein
C57Bl6/J mice 30 mg/kg ↓Weight gain Alleviated MNCV
and SNCV deficits in
diabetic mice
↓ Diabetes-associated nitrated protein accumulation in
sciatic nerve and normalized this variable in spinal cord Stavniichuk et al. [119]
Did not affect non-fasting glycemia
↓ 12(S) hydroxyeicosatetraenoic acid concentrations but
did not alter sciatic nerve and spinal cord LO
overexpression
Sex not specified Intraperitoneal Ameliorated thermal hypoalgesia andtactile allodynia in diabetic mice
Normalized sciatic nerve phosphorylated p38 MAPK
expression without affecting total p38 MAPK
expression
Genistein Male C57BL/6J mice
3 and 6 mg/kg
Did not alter blood glucose
concentrations or body weight decrease
or decrease hyperglycemia
-
↓ Pro-inflammatory cytokines TNFα, IL-1β and IL-6,
ROS levels in sciatic nerves; MDA and ROS levels in
brain and liver; iNOS in thoracic aorta
Valsecchi et al. [93]↑ NGF, eNOS and SOD
Did not modify decreased cerebral activities of CAT
and GPx
Restored hepatic GPx activity but it did not modify
CAT activity decrease
Subcutaneous ↑ Diabetes-induced mechanicalallodynia
Restored the GSH content and the GSH and GSSG ratio
in liver but did not modify total glutathione content
Pelargonidin Male Albino Wistar
rats
10 mg/kg
Administration for 8 weeks prevented
weight loss and reduced serum glucose
level -
↓ Increased MDA content and nitrite levels
Mirshekar et al. [91]
↓ Serum glucose level
↑ Increased SOD level
Oral gavage Ameliorated thermal hyperalgesia byincreasing tail-flick response latency
↑ = Enhanced/Increased, ↓ = Attenuated/Decreased/Reduced/Suppressed, X = Inhibited/Prevented.
Molecules 2020, 25, 1171 17 of 36
7. Other Peripheral Nerve Injury Models
Majority of the neuropathic pain models use nerve injury model to induce hyperalgesia and
allodynia in rodents. These models represent similarity with human neuropathic pain. Several models
in rodents have developed with a mixture of intact and injured peripheral nerve fibers. Moreover,
different types of nerve lesions, such as crush, complete or partial tight ligation, loose ligation with
inflammatory materials and cryoneurolysis have been employed to study neuropathic pain conditions.
The type of nerve lesion determines the character of the ongoing neuropathic pain. The following
section of the review will focus on a few peripheral nerve injury models and the effects of flavonoids
on those peripheral nerve injury models [124].
7.1. Sciatic Nerve Chronic Constriction Injury (CCI)
CCI is one of the most widely studied models for chronic neuropathic pain. The model was
first developed by Bennett and Xie [125] and it resembles human neuropathy, resulting from trauma
of peripheral nerves with nerve entrapment or compression. The model is produced by exposing
the sciatic nerve on one side by making a skin incision and cutting through the connective tissues
between the gluteus superficialis and biceps femoris muscles. At 1-mm intervals, four chromic gut
ligatures are loosely tied around the sciatic nerves to just obstruct but not prevent the epidural blood
flow. The wound is covered by placing sutures in the muscles and staples in the skin [125]. CCI leads
to intraneural edema by strangulating the nerve and axotomizing nerve axons. CCI also results in
thermal hyperalgesia and mechanical allodynia in mice model of CCI [126].
7.2. Effects of Flavonoids on Sciatic Nerve CCI Model
Table 5 summarizes the effects of flavonoids on CCI-induced neuropathic pain. CCI-induced
pain includes several symptoms, including spontaneous (tingling, burning, electric-shock like) pain,
dysesthesia, paraesthesia, allodynia, and hyperalgesia [127]. Flavonoids diosmin [128], hesperidin [129],
and grape seed proanthocyanidins [130] reduced both thermal and mechanical hyperalgesia, whereas
isoorientin [131], morin [132], EGCG [133], epigallocatechin derivate compounds 23 and 30 [134],
and genistein [135] reduced only thermal hyperalgesia. Quercetin has been reported to reduce
thermal and mechanical hypersensitivities in a superior degree compared to gabapentin and
morphine [136]. Furthermore, pre-injury administration of quercetin showed long term effects
on mechanical hypersensitivity, indicating the antinociceptive effects of quercetin in CCI model [136].
CCI-induced mechanical allodynia has been reduced by isoorientin [131], morin [132], puerarin [115],
EGCG [133], and genistein [135]. Isoorientin [131] and morin [132] reduced cold allodynia. Luteolin
has been reported to reduce cold and mechanical hyperalgesia, but not thermal hyperalgesia [137]. On
the other hand, fisetin reduced thermal hyperalgesia, but not nociceptive sensitivity to mechanical
stimuli [99].
In CCI model of neuropathic pain, oxidative/nitrosative stress and antioxidant enzymes (SOD
and GSH) play important roles in the neuropathology and behavioral consequences [108,138].
Oxidative/nitrosative stress depletes the antioxidative enzymes and amplifies inflammatory processes
in DRG, nerve and spinal [138,139]. The antioxidative enzymes SOD and CAT play important roles in
balancing between the oxidative and prooxidative systems by scavenging free radicals and preventing
peroxidative stress reaction [140]. Studies have shown that systematic injections of antioxidant reduced
heat hyperalgesia [141,142]. Co-treatment of morphine with grape seed proanthocyanidins (GSPE)
increased the levels of GSH, SOD, CAT, nitrate, and decreased MDA level as compared to the individual
treatment with morphine or GSPE [130]. Morin restored GSH level and decreased nitrite level in
the spinal cord [132] and genistein decreased the levels of ROS and MDA, increased GPx and CAT
activities to combat the oxidative stress, as well as normalized nerve-injury-induced inducible nitric
oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS) [135] in CCI model of neuropathic
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pain. Another study showed that isoorientin increased the levels of T-AOC, T-SOD, and CAT, and
decreased MDA levels in CCI operated mice [131].
The increased level of nitro oxidative stress leads to the DNA damage, which in turn activates
PARP, resulting in PARP-mediated DNA repair by transferring ADP-ribose units to the nuclear proteins.
However, PARP activation leads to the activation of NF-κB, which in turn leads to the activation of
pro-inflammatory markers, such as cyclooxygenase-2 (COX-2), iNOS, TNF-α, and IL-6, playing a
major role in pain processing events [143,144]. The effects of flavonoids on different pro-inflammatory
biomarkers have also been reported in CCI-induced neuropathic pain model [128]. Single treatment of
diosmin reduced the mRNA expressions of IL-1β, IL-33, and St2, whereas prolonged treatment reduced
the mRNA expression of TNFα along with IL-1β, IL-33, and St2. On the other hand, a single treatment
reduced the expressions of microglia (Iba-1) and oligodendrocytes (Olig2) and prolonged treatment
reduced astrocytes (Gfap) along with microglia and oligodendrocytes [128]. Another study showed that
puerarin reduced the enhanced immunoreactivity of Iba-1 and GFAP, which are microglia and astroglia
activation marker, respectively [115]. Morin reduced several inflammatory biomarkers (PARP, iNOS,
COX-2, NF-κB and phospho-NF-κB, TNF-α and IL-6) in CCI-induced neuropathic pain model [132].
CCI-induced nerve injury causes the increase in DNA damage, resulting in the overactivation of
PARP enzyme [145]. PARP overactivation leads to bioenergetic failure because overaction of PARP
consumes a high amount of nicotinamide adenine dinucleotide (NAD) during DNA repair, and finally
NAD synthesis consumes ATP, leading to the failure of ATP-dependent biochemical processes [146].
Morin treatment significantly restored CCI-induced depleted ATP levels and recused the neuronal cells
from bioenergetic crisis [132]. Kuang et al. [133] reported that EGCG treatment decreased the mRNA
and protein expressions of toll-like receptor (TLR4) and its endogenous ligand HMGB1. TLR4 is a
pattern recognition receptor and involved in immune and inflammatory disease. Once the endogenous
ligand binds to the TL4R, the receptor gets activated and induces the production of pro-inflammatory
cytokines via activation of NF-κB [147,148]. Moreover, EGCG decreased downstream pro-inflammatory
cytokines (IL-1β and TNF-α) of TLR4 signaling pathway, increased anti-inflammatory cytokine (IL-10),
and downregulated NF-κB expression in lumbar spinal dorsal horn of CCI rats [133]. In another study
EGCG and its derivate compound 30 but not compound 23 reduced mRNA and protein expressions of
TNF-α, IL-1β, IL-6 in dorsal horn of spinal cord [134]. Furthermore, EGCG and compound 30 but not
compound 23 reduced NF-κB protein expression in dorsal horn of spinal cord [134]. The treatment
of puerarin, and isoorientin also attenuated CCI-induced pro-inflammatory cytokines (TNF-α, IL-1β,
IL-6) [115,131]. Genistein also downregulated mRNA expressions of both IL-1β and IL-6 in sciatic
nerve and protein expression of IL-1β in DRG and spinal cord [135].
Puerarin attenuated the overexpression of NF-κB and nuclear translocation of p65 [115], whereas
genistein abolished the activation of NF-κB but did not alter its transcription in the spinal cord [135].
The expression of protein expression of NF-κB in the dorsal horn of spinal cord was attenuated by
EGCG and compound 30 but not compound 23 [134].
Peripheral nerve constriction is commonly associated with loss of sensory function, mainly
connected to the nerve fiber structure damage. Zhang et al. [131] reported isoorientin effectively
increased the amplitude of SNCV and sensory nerve action potential (SNAP) after CCI surgery,
indicating the ameliorative properties of isoorientin in CCI-induced nerve damage. Furthermore,
isoorientin showed neuroprotective effects by restoring the disordered arrangement of myelinated
nerve fibers, neuronal gaps, axon separation after CCI operation. Isoorientin also reduced the MMP-9
expression as well as overexpressed astrocytes and microglia in CCI operated mice [131]. MMP-9 is
required for the activation of glial cell via activating pro-inflammatory cytokines [106,149]. In another
study, morin treatment improved sciatic functional index (SFI) but was unable to completely recover
to the normal SFI. Furthermore, morin decreased the spontaneous pain behavior and corrected foot
deformity by showing no postural deficits [132].
Zhao et al. [99] explored the antinociceptive activity of fisetin, a 3,3′,4′,7-tetrahydroxyflavone,
in a mouse neuropathic pain model after performing sciatic nerve CCI. The study found that fisetin
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exerted antihyperalgesic effect in CCI-induced animals by activating descending monoamine system
with markedly increasing spinal monoamine (serotonin) levels and the ratio of 5-HT/5-HTP, and
concomitantly decreasing spinal monoamine oxidase A (MAO-A). Furthermore, the study showed
antihyperalgesic activity of fisetin was abolished by co-administration of 5-HT7 receptor antagonist
(SB-258719), indicating the involvement of 5-HT7 in the fisetin-induced antinociceptive activity.
Fisetin also attenuated the co-morbid depressive and anxiety-like behaviors developed following
2-3 weeks CCI surgery, as shown by the increased immobility time in forced swim test, increased
latency to feed in novelty suppressed feeding test, and deceased lit compartment time in light-dark
test [99]. In another study, the significant antihyperalgesic effect induced by the combination of
hesperidin with diosmin was abolished by the presence of naloxone (opioid receptor antagonist),
bicuculline (GABAA receptor antagonist), and haloperidol (D2 receptor antagonist), indicating the
involvement of the afore-mentioned receptors in hesperidin-diosmin-induced antihyperalgesia in CCI
model of neuropathic pain [129]. In another study, co-treatment of grape seed proanthocyanidins
with morphine enhanced the antihyperalgesic activity of morphine and reduced morphine-induced
tolerance [130]. Luteolin has also been reported to possess antihyperalgesic effects in the spinal cord
via γ-aminobutyric acidA (GABAA) and µ-opioid receptors as evident by employing GABAA and
opioid receptor antagonists bicuculline and naloxone, respectively, but not via benzodiazepine and
glycine receptors as evident by the application of benzodiazepine and glycine receptor antagonists,
flumazenil and strychnine, respectively. Furthermore, supraspinal administration of luteolin showed
no antihyperalgesic effects, indicating that this region is unlikely to contribute in antihyperalgesic
effects of luteolin. Moreover, only high concentration of luteolin inhibited motor function, evident
in rotarod latency experiment [137]. In another study, by employing inhibitors for NOS (L-NAME),
soluble guanylate cyclase (ODQ), PKG (KT5823), and ATP sensitive potassium K+ channels, diosmin
has been reported to inhibit CCI-induced thermal and mechanical hyperalgesia by activating
NO/cGMP/PKG/KATP channel signaling pathway [128]. Valsecchi et al. [135] reported that the
antinociceptive activities of genistein was mediated by ERβ because the treatment with ERβ-specific
antagonist PHTPP abrogated its antinociceptive activities. The involvement of ERβ in attenuating
CCI-induced neuropathic pain could be explained by the greater affinity of genistein towards ERβ
than ERα [150]. The neuropathic pain is also induced by the enhancement of N-methyl-d-aspartate
receptor (NMDAR) through the expression of NMDAR2B subunit in the dorsal horn of spinal cord [151].
Xifró et al. [134] reported the involvement of NMDAR in CCI-induced neuropathic pain in which
EGCG derivative compound 30 but not EGCG and another compound 23 reduced phosphorylation
and protein expression of NMDAR receptor subunit NMDAR2B in the dorsal horn of the spinal cord.
Xifró et al. [134] also reported that EGCG and compound 30 but not compound 23 reduced fatty acid
synthase activity (FASN) in dorsal horn of spinal cord. Although, EGCG and compounds 23 and 30
showed no effects on FASN protein expression. FASN has been well reported to play important role in
neuropathic pain followed by peripheral nerve injuries [152–154].
7.3. Partial Sciatic Nerve Injury (PNI)
The partial sciatic nerve ligation model is created by ligating the dorsal third to half of the common
sciatic nerve at the upper-thigh level [155]. Briefly, the left hind leg of rat is shaved and dissected to
expose the sciatic nerve at the upper-thigh level. Using 8-0 silk suture, the dorsal one-third to sciatic
nerve is tightly ligated just distal to the point at which thr posterior biceps semitendinosus nerve
branches off [155]. A similar model developed by Malmberg and Basbaum [156] also used to study
neuropathic pain and development of new therapeutics [157–160].
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Table 5. Effects of flavonoids on sciatic nerve chronic constriction injury (CCI).
Flavonoids Animals
Flavonoids (Dose
mg/kg and Route of
Administration)
Effects/Mechanisms of Action Reference
Behavioral Evaluation/Other
CCI-Induced Parameters
Electrophysiological/
Functional
Evaluation
Histopathological/Biochemical/Molecular
Parameters
Isoorientin
Male pathogen-free
Institute of Cancer
Research (ICR) mice
7.5, 15, and 30 mg/kg
↓ CCI-induced mechanical and cold
allodynia and thermal hyperalgesia
Restored
CCI-induced
SNCV and SNAP
↑ Levels of total antioxidant capacity (T-AOC), total
superoxide dismutase (T-SOD), CAT
Zhang et al. [131]
Intragastrical
↓MDA concentrations
X MMP-9, astrocyte, microglia overexpression in
spinal cord
↓ Protein expressions of TNF-α, IL-6, and IL-1β in
spinal cord
Ameliorated CCI-induced histopathological changes,
such as disordered myelinated nerve fibers, swollen
axons, and neuron gaps, abnormal ultrastructure of
sciatic nerve and reduced abnormal myelin sheath
percentage
Diosmin Male Swiss mice
1, 10 mg/kg X CCI-induced mechanical and
thermal hyperalgesia by
NO/cGMP/PKG/KATP channel
signaling pathway
-
Single treatment—X mRNA expressions of spinal
cord cytokine (IL-1β, IL-33, St2)
Bertozzi et al. [128]Prolonged treatment—↓ TNFαmRNA expression in
spinal cord
Intraperitoneal
Single treatment—X Glial cells activation microglia
(Iba-1), oligodendrocytes (Olig2)
Prolonged treatment—X (Gfap), Iba-1, and Olig2
mRNA expressions
Diosmin and
Hesperidin Male Wistar rats
Hesperidin (10, 100,
316.2, 562.3, 1000
mg/kg), Diosmin (10,
100 mg/kg)
Hesperidin—↓Mechanical and
thermal hyperalgesia -
Combined antihyperalgesic activity mediated by D2,
GABAA, and opioids receptors, but not 5-HT1A
receptor
Carballo-Villalobos et al. [129]
Intraperitoneal Hesperidin + Diosmin − Improvedantihyperalgesic activity
Quercetin Male Wistar rats 100 mg/kg
Alleviated mechanical and thermal
hypersensitivity higher than
morphine and gabapentin
- - Çivi et al. [136]
Pre-injury administration showed
long-term effects on mechanical
hypersensitivity
Grape seed
Proanthocyanidins
(GSPE)
Wistar rats 100 and 200 mg/kg ↓Mechanical and thermal
hyperalgesia
-
↓MDA and nitrate levels in sciatic nerves
Kaur et al. [130]Co-treatment of GSPE and morphine attenuated
morphine tolerance, enhanced antihyperalgesic
activity
Either sex Oral gavage ↑ GSH level, SOD, and CAT compared toGSPE-alone- and morphine-alone treatments
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Table 5. Cont.
Flavonoids Animals
Flavonoids (Dose
mg/kg and Route of
Administration)
Effects/Mechanisms of Action Reference
Behavioral Evaluation/Other
CCI-Induced Parameters
Electrophysiological/
Functional
Evaluation
Histopathological/Biochemical/Molecular
Parameters
Morin
Male
Sprague-Dawley rats
15 and 30 mg/kg
Improved CCI-induced thermal
hyperalgesia, mechanical and cold
allodynia
Improved SFI but
did not
completely
recover to normal
SFI
Restored levels of GSH, ATP
Komirishett et al. [132]↓ Nitrite levels in spinal cord
Oral gavage ↓ Spontaneous pain, corrected foot
deformity
↓ Inflammatory markers (PARP, iNOS, COX-2, NF-κB
and phospho-NF-κB, TNF-α and IL-6) in spinal cord
↓ poly (ADP) ribose (PAR) and NF-κB levels
EGCG and its two
synthetic derivative
compounds 23 and 30
Female Balb-c mice
10, 30, 50 and 100
mg/kg EGCG and compound 30 but not
compound 23—↓ CCI-induced
thermal hyperalgesia
-
EGCG and compound 30 but not compound 23—↓
FASN in dorsal horn of spinal cord
Xifró et al. [134]
Intraperitoneal
EGCG and compounds 23 and 30—No effects on
FASN protein expression
EGCG and compound 30 but not compound 23—↓
mRNA and protein expressions of TNF-α, IL-1β, IL-6
in dorsal horn of spinal cord
EGCG and compound 30 but not compound 23—↓
NF-κB protein expression in dorsal horn of spinal
cord
Compound 30 but not EGCG and compound 23—↓
Phosphorylation and protein expression of NMDAR
receptor subunit NMDAR2B in dorsal horn of spinal
cord
Fisetin Male C57BL/6J mice
5, 15 and 45 mg/kg
↓ CCI-induced thermal hyperalgesia
but not nociceptive sensitivity to
mechanical stimuli
-
↓ Escalated MAO-A to level like non-injured animals
but did not affect MAO-B in sham or CCI mice Zhao et al. [99]
Oral gavage ↓ CCI-induced co-morbid depressiveand anxiety-like behaviors
Exhibited antinociceptive activity with involvement
of serotonergic system (coupled with 5-HT7)
Luteolin
Male
Sprague-Dawley rats
0.1–1.5 mg
Spinal administration reduced cold
and mechanical, but not thermal
hyperalgesia by activating GABAA
receptors in a flumazenil-insensitive
manner and µ-opioid receptor
- - Hara et al. [137]
Intrathecal or
intracerebroventricular
Supraspinal administration showed
no antihyperalgesic activity
High concentration inhibited motor
function
Puerarin
Male
Sprague-Dawley rats
4, 20, and 100 nM
↓ CCI-induced mechanical allodynia -
X Activation of microglia and astroglia in spinal
dorsal horn Liu et al. [115]
Intrathecal
↓ TNF-α, IL-1β, IL-6, DNA binding activities,
overexpression of NF-κB as well as nuclear
translocation of p65
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Table 5. Cont.
Flavonoids Animals
Flavonoids (Dose
mg/kg and Route of
Administration)
Effects/Mechanisms of Action Reference
Behavioral Evaluation/Other
CCI-Induced Parameters
Electrophysiological/
Functional
Evaluation
Histopathological/Biochemical/Molecular
Parameters
EGCG
Male
Sprague-Dawley rats
1 mg/kg
Improved CCI-induced mechanical
allodynia and thermal hyperalgesia
-
↓ IL-1β and TNF-α
Kuang et al. [133]↑ Anti-inflammatory cytokine (IL-10)
Intrathecal
↓mRNA and protein expressions of TLR4 and
HMGB1
↓ NF-κB expression in lumbar spinal dorsal horn
Genistein Male C57BL/6J mice
1, 3, 7.5, 15, and 30
mg/kg Reversed CCI-induced thermal
hyperalgesia and mechanical
allodynia
-
↓mRNA expressions of both IL-1β and IL-6 in sciatic
nerve and protein expression of IL-1β in DRG and
spinal cord
Valsecchi et al. [135]
Subcutaneous
↓ ROS and MDA levels
↑ GPX and CAT activities in CCI operated animals
X NF-κB activation but did not modify NF
transcription in spinal cord
Normalized nerved injury-induced increase of iNOS
and nNOS
↑ = Enhanced/Increased, ↓ = Attenuated/Decreased/Downregulated/Reduced/Suppressed, X = Abolished/Inhibited/Prevented.
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7.4. Spared Nerve Injury (SNI)
The SNI model involves selective injury of two (peroneal and tibial nerves) of the three terminal
branches of the sciatic nerve, leaving the third branch (sural nerve) intact [161]. The model produced
pain hypersensitivity in the territory of spared sural nerve, which is similar to the stimulus-evoked
pain observed in clinical neuropathic pain syndromes [161,162].
7.5. Spinal Nerve Ligation (SNL)
The SNL model consists of unilateral and tight ligation of L5 and/or L6 spinal nerves of rodents at
a distal location of dorsal root ganglia. The SNI model simulates human causalgia and was developed
by Kim and Chung [163]. SNI model leads to increased sensitivity to heat and other non-painful
mechanical stimuli [164]. Furthermore, allodynia and hyperalgesia develop quick after ligation and
persist for at least four months exhibiting spontaneous pain behaviors, like guarding, licking, and
lifting of the ipsilateral hind paw, but without autotomy behavior The ligation of L5/L6 spinal nerve
ligation was developed by Kiso et al. and is useful in studying neuropathic pain [165]. The mechanical
allodynia begins at day 1 and lasts for two months post-surgery in the L5/L6 spinal nerve ligation model.
7.6. Effects of Flavonoids on Other Peripheral Neuropathic Pain Models
Table 6 summarizes the effect of flavonoids on other peripheral neuropathic pain models.
SNL-induced mechanical allodynia has been reduced by baicalein [166], EGCG [167], and myricetin [168].
Baicalein [166] and myricetin [168] attenuated SNL-induced thermal hyperalgesia, whereas quercetin
attenuated both thermal and cold hyperalgesia in SNL rats [169]. Moreover, pre-administration of
quercetin attenuated neuropathic symptoms [169]. In addition to inhibiting neuropathic pain behavior in
SNL rats, quercetin inhibited inflammatory response by inhibiting pro-inflammatory cytokines TNF-α
and IL-1β and reduced CCL-2 and MMPs [169], which play important roles in the pathogenesis of
neuropathic pain [105,170]. The study further confirmed that quercetin inhibited TLR signaling pathway
and NF-κB through activating transforming growth factor-β-activated kinase (TAK-1) [169]. Baicalein
has been reported to reverse global histone-H3 acetylation and suppress HDAC1 expression [166].
Histone acetylation is catalyzed by histone acetyltransferases and removed by histone deacetylases
(HDACs) [171]. Studies have shown that pharmacological intervention on the process of histone
acetylation can affect pain behavior. Systematic and intrathecal administration of HDAC inhibitors
provide analgesic effects in inflammatory pain models, indicating that inhibition of histone acetylation
might be useful in pain management [172,173]. EGCG has been reported to completely block the
neuronal NOS (nNOS) expression, but it failed to inhibit iNOS expression in SNL-induced animals [167].
Both nNOS and iNOS play important roles in mechanical hypersensitivity after peripheral nerve injury
and NOS inhibitors reverse or reduce mechanical allodynia and thermal hyperalgesia in neuropathic
pain [160,174]. Neuronal NOS (nNOS) is predominantly found in central nervous system and is
constitutively expressed and activated by calcium signals and iNOS is activated by the pro-inflammatory
cytokines and is calcium-independent [175–177]. Hagenacker et al. [168] reported that myricetin at
low concentrations reduced voltage activated calcium channel currents (ICa(V)). The reduction was
abolished by blocking with a PKC inhibitor chelerythrine but not by a p38 inhibitor SB203580. In
contrast, high concentrations of myricetin increased voltage activated calcium channel currents (ICa(V))
in vitro mediated by p38 but not by PKC.
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Table 6. Effects of flavonoids on other peripheral neuropathic pain models.
Flavonoids Animals
Flavonoids (Dose
mg/kg and Route
of Administration)
Effects/Mechanisms of Action Reference
Behavioral Evaluation Electrophysiological/Functional Evaluation Biochemical/MolecularParameters
SNI
Quercetin
Male
Sprague-Dawley
rats
0.1, 1% Pre-surgery administration—↓Mechanical allodynia -
X GFAP in satellite glial cells of
ipsilateral L5 DRG Muto et al. [179]
Oral gavage Post-surgery administration—Didnot affect SNI-induced pain
SNL
Quercetin
Sprague
Dawley rats 10–100 mg/kg
Single or continuous
administration—↓ SNL-induced
thermal and cold hyperalgesia -
↓ Phosphorylation of TAK1, IKK
and JNK2 in cultured astrocytes Ji et al. [169]
Sex not
specified
Oral gavage
Pre-surgery administration—↓
Neuropathic pain symptoms when
administered
X NF- activity via TAK1 in
HEK293 cells
↓ Protein expressions of TNF-α
and IL-1β; mRNA expressions of
MMP- 9, MMP-2 and CCL2
Baicalin Male Wistar
rats
10 µg
↓ SNL-induced mechanical
allodynia and thermal
hyperalgesia
-
Reversed histone-H3 acetylation
and HDAC1 expression of
SNL-induced spinal cord dorsal
horn
Cherng et al. [166]
Intrathecal ↑Antinociceptive activity ofmorphine
Epigallocatechin-
3-gallate
Male Sprague
Dawley rats
10–50 mg/kg ↓ SNL-induced mechanical
allodynia
- X nNOS expression in spinal
cord of SNL rats
Choi et al. [167]
Intrathecal
Myricetin Male Wistar
rats
0.1–10 mg/kg ↓ SNL-induced mechanical
allodynia and thermal
hyperalgesia
Low concentrations—↓ Voltage activated calcium channel
currents (ICa(V)) in vitro mediated by PKC but not p38 - Hagenacker et al. [168]Intraperitoneal
0.1–5 µM (low)
10–100 µM
(high)—In vitro
High concentrations—↑ Voltage activated calcium
channel currents (ICa(V)) in vitro mediated by p38 but not
PKC
Partial sciatic nerve ligation
Hesperetin Wistar rats 20, 50 mg/kg
↓ Partial sciatic nerve
ligation-induced mechanical and
thermal hyperalgesia and
mechanical allodynia
↑Motor nerve conduction velocity
↓ TNF-αmRNA expression in
sciatic nerve Aswar et al.
2014 [178]
Either sex Oral gavage
↓ Different tissue biomarkers,
such as total protein, NO, lipid
peroxidase, IL-1β and IL-6
↑ = Enhanced/Increased, ↓ = Attenuated/Decreased/Downregulated/Reduced/Suppressed, X = Blocked/Inhibited/Prevented.
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Besides SNL, flavonoids quercetin and hesperetin have been reported to reduce SNI and partial
sciatic nerve ligation-induced neuropathic pain [178,179]. Muto et al. [179] evaluated the effect of
quercetin on SNI model in which administration of quercetin before surgery attenuated mechanical
allodynia but post-administration did not show any effect on the SNI-induced pain. Furthermore,
quercetin treatment inhibited glial fibrillary acidic protein (GFAP) in satellite glial cells of ipsilateral
L5 DRG. Aswar et al. [178] reported that hesperetin attenuated partial sciatic nerve ligation-induced
mechanical and thermal hyperalgesia and mechanical allodynia along with downregulation of TNFα
mRNA expression in sciatic nerve and different tissue biomarkers, such as total protein, NO, lipid
peroxidase, and interleukins IL-1β and IL-6.
8. Future Directions
The present review evaluates the antinociceptive effects of flavonoids on different neuropathic
pain conditions. The structurally effective flavonoids consist of catechol substructure on either A- or
B- ring, together with the presence of C3 OH group of C-ring along with an oxo group on C4. The
protective effects of flavonoids are enhanced by a double bond in between C2 and C3 due to the
formation of a planar molecule or increase in the double bond conjugation in the flavonoids [180].
A study on structure-antioxidant activity relationships reported the protective effects of flavones,
flavanones, and flavanols isolated from the resinous exudate of Heliotropium sinuratum due to the
presence of 3-OH group [181]. The presence of 5-OH together with 4-oxo group contributed to the
activity but only in presence of 3-oxo group. However, without 3-oxo group, the 5-OH with 4-oxo
group is inactive.
The present review also focuses on the effects of flavonoids in combating oxidative stress either by
increasing the levels of antioxidant enzymes or by decreasing the levels of ROS or other oxidative stress
biomarkers in different peripheral neuropathic conditions [72,73,89,91–93,96–99,111,114,130–132,135].
Furthermore, studies have demonstrated that the antioxidant properties of flavonoids could be attributed
to the increase in phenolic hydroxyls, replacement of C-3′,4′ positions in the B ring of flavonoids by
hydroxyls, and the presence of a methoxyl group at the ortho position of phenolic hydroxyl [182]. Besides
flavonoids, the structure-activity relationships of phytoestrogens and other phytochemicals are also
known to enhance the cytotoxic and antiproliferative activities of breast carcinomas [183,184].
Therefore, the antioxidant as well as antineuropathic properties of flavonoids against different
peripheral neuropathic pain conditions could be enhanced by modulating the structure-function
relationships, mainly by replacing or adding different functional groups to the core flavonoid
structures [180]. In addition to structure-activity relationships, future preclinical as well as clinical
studies must also explore other mechanisms that may be implicated in the flavonoid-mediated
amelioration of different peripheral neuropathic conditions. Future research studies must address the
role of flavonoids in models of diabetes and its complications, as well as opioid use and chronic pain,
which are of huge public health and economic concern globally.
9. Overall Conclusions
The use of conventional analgesics, such as non-steroidal anti-inflammatory drugs, opioids, tricyclic
antidepressants, and anti-convulsants are reported to exhibit a wide spectrum of adverse side effects,
which limit the use of these drugs in treating neuropathic pain conditions. Hence, the search for alternative
therapeutics with less side effects to attenuate peripheral neuropathic pain has led the researchers to identify
and synthesize drugs from natural sources. The present review sheds light on the effects of flavonoids
in attenuating peripheral neuropathic pain conditions. The data reported in these studies support that
flavonoids are effective in attenuating neuropathic pain in different models, such as spared nerve injury,
spinal nerve ligation, partial sciatic nerve injury, diabetes-induced neuropathy, chemotherapy-induced
neuropathy, CCI, and related models at behavioral, biochemical, electrophysiological, histopathological,
and molecular levels. Figure 1 summarizes the effects of flavonoids on peripheral neuropathic conditions
based on the studies reported in the present review (Figure 1).
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Figure 1. Effects of flavonoids on peripheral neuropathic conditions. Flavonoids attenuate different peripheral neuropathic pain conditions by inhibiting or 
downregulating different neuroinflammatory, cellular, bioenergetic and oxidative stress markers. The illustration was created with BioRender 
(http://BioRender.com). 
Figure 1. Effects of flavonoids on peripheral neuropathic con iti s. l ids attenuate different peripheral neuropathic pain conditi s by i hi iting or
downregulating different ne flammatory, cellular, bioenergetic and oxidative stress mark rs. The illustr tion was created wi h B Render (http://BioRender.com).
Molecules 2020, 25, 1171 27 of 36
In conclusion, the present review provides important insights into the effects of flavonoids in
alleviating different peripheral neuropathic pain conditions and how each of the flavonoids modulate
different pain biomarkers in rodent models of peripheral neuropathy. Thus, there is much potential for
the development of flavonoid-based potent neuropathic pain-relieving drugs in future.
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